Skip Navigation

European Heart Journal 2004 25(23):2170-2171; doi:10.1016/j.ehj.2004.09.016
Copyright © 2004 by the European Society of Cardiology.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Eriksson, P.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Eriksson, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Letter to the Editor

Reply: Long-term clopidogrel following PCI: marginal antithrombotic effects are offset by increased bleeding risks

Peter Eriksson*

Interventional Cardiology Laboratory, Heart Centre, University Hospital, S-901 85 Umeå, Sweden

* Tel.: +46 (0)90 785 69 25; fax: +46 (0)90 13 76 33 (E-mail: peter.eriksson@medicin.umu.se).

The first 10% of the full text of this article appears below.

Dear Sir,

Dr. Steinhubl and Dr. Topol, authors of CREDO,1 disagree with my analysis of long-term clopidogrel therapy after percutaneous coronary intervention (PCI) in the PCI–CURE and CREDO trials.2 However, their arguments seem biased and misleading.

The CURE trial3 showed a minor absolute reduction of 1.1% (p=0.009) in . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?